BC-3425 is under clinical development by Wuxi Biocity Biopharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BC-3425’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BC-3425 is under development for the treatment of solid tumor. The therapeutic candidate is a monoclonal antibody which acts by targeting 4-1BB (CD137). It is being developed based on OMT all-human technology.
Wuxi Biocity Biopharma overview
Wuxi Biocity Biopharma is a biotechnology research company that focuses on developing biological mechanisms in the fields of tumor signal transduction pathways and cellular immune responses for tumors, chronic kidney diseases, and other diseases. The company is headquartered in Wuxi, Jiangsu, China.
For a complete picture of BC-3425’s drug-specific PTSR and LoA scores, buy the report here.